{"id":324010,"date":"2026-03-11T10:41:07","date_gmt":"2026-03-11T10:41:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/324010\/"},"modified":"2026-03-11T10:41:07","modified_gmt":"2026-03-11T10:41:07","slug":"why-this-asx-healthcare-stock-has-crashed-20-today","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/324010\/","title":{"rendered":"Why this ASX healthcare stock has crashed 20% today"},"content":{"rendered":"\n

Shares in\u00a0Imugene Ltd\u00a0(ASX: IMU<\/a>) are tumbling on Wednesday after the cancer immunotherapy company returned from a\u00a0trading halt<\/a>.<\/p>\n

At the time of writing, the Imugene share price is down 19.57% to 18.5 cents. The stock is now down roughly 40% since the start of 2026. <\/p>\n

The company requested the halt yesterday while it prepared an update for investors.<\/p>\n

Here is what the company revealed. <\/p>\n

\"Close-up<\/p>\n

Image source: Getty Images<\/p>\n

Imugene announces $20 million capital raising <\/p>\n

According to its\u00a0announcement<\/a>, Imugene is planning to raise up to $20 million through a combination of a placement and a share purchase plan (SPP). <\/p>\n

The company has already secured firm commitments for a $12 million placement from institutional and sophisticated investors. These investors will subscribe for approximately 66.7 million new shares at 18 cents each.<\/p>\n

That price represents a 21.7% discount to the last closing price of 23 cents on 9th March and about a 20.8% discount to the 5-day\u00a0VWAP<\/a>. <\/p>\n

Imugene will also launch a share purchase plan to raise up to $8 million, allowing eligible shareholders to apply for new shares at the same 18-cent price.<\/p>\n

The SPP will allow investors to apply for up to $30,000 worth of shares.<\/p>\n

Investors participating in the placement and SPP will also receive free attaching options. These options have an exercise price of 18 cents and expire in April 2027. <\/p>\n

Why Imugene is raising fresh capital <\/p>\n

Management says the funds will be used to continue advancing its lead cancer therapy program known as azer-cel.<\/p>\n

This therapy is an allogeneic CAR-T treatment being developed to treat blood cancers.<\/p>\n

The proceeds will support the ongoing Phase 1b clinical trial of azer-cel, including expansion of cohort 2 and the new cohort 3 BTKi combination study.<\/p>\n

The funding will also help extend the company’s cash runway into the fourth quarter of 2026.<\/p>\n

Imugene said the trial program aims to generate additional clinical data that could support future regulatory progress.<\/p>\n

Encouraging clinical data emerging <\/p>\n

The company has\u00a0previously reported<\/a>\u00a0promising early results from the azer-cel program.<\/p>\n

Early phase 1b trial results showed an overall response rate of about 82% in relapsed or refractory diffuse large B cell lymphoma (DLBCL) patients.<\/p>\n

The therapy is designed as an off-the-shelf CAR-T treatment that can be manufactured in advance rather than customised for individual patients.<\/p>\n

If successful, this approach could offer faster treatment access and lower manufacturing costs compared with traditional CAR-T therapies.<\/p>\n

What investors should watch next <\/p>\n

Imugene plans to continue enrolling patients in its clinical trials and generate additional data throughout 2026.<\/p>\n

The company is also exploring combination strategies involving BTK inhibitors, which could expand the therapy’s potential applications. <\/p>\n

However, the sizeable discount on the new shares appears to be weighing on the share price today.<\/p>\n","protected":false},"excerpt":{"rendered":"Shares in\u00a0Imugene Ltd\u00a0(ASX: IMU) are tumbling on Wednesday after the cancer immunotherapy company returned from a\u00a0trading halt. At…\n","protected":false},"author":2,"featured_media":324011,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[134,527,111,139,69],"class_list":{"0":"post-324010","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-new-zealand","11":"tag-newzealand","12":"tag-nz"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/324010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=324010"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/324010\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/324011"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=324010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=324010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=324010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}